Asha Therapeutics is looking to test the therapeutic activity of their novel SARM1 inhibitor as a potential treatment option for CMT2A. CMT2A is caused by mutations in the MFN2 gene, leading to mitochondrial dysfunction and nerve degeneration. Prior studies have shown that genetic removal of SARM1, a key driver in nerve degeneration, prevents disease in CMT2A animals. Dr. Bradlee Heckmann, PhD, will walk us through Asha’s approach and the status of the project funded by CMTRF in early 2025.

Date: November 6, 2025
Time: 7:00 p.m. ET
Location: Zoom

There is no cost to attend. To register, click here.